伊维菌素在COVID-19的临床应用析论
The Clinical Application of Ivermectin in COVID-19
DOI: 10.12677/OJNS.2023.112020, PDF,    科研立项经费支持
作者: 车土玲*, 蓝 萍, 余春森：宁德师范学院医学院，福建 宁德；苏裕盛#：宁德师范学院医学院，福建 宁德；宁德师范学院毒物与药物毒理学重点研究室，福建 宁德
关键词: 伊维菌素；IVM；COVID-19；Ivermectin； IVM； COVID-19
摘要: 伊维菌素(Ivermectin, IVM)是美国食品药品管理局(Food and Drug Administration, FDA)批准的广谱抗寄生虫药，已证明对多种DNA和RNA病毒具有抗病毒活性，包括SARS-CoV-2，加上成本低廉、可用性强、耐受性和安全性良好，在COVID-19的临床应用中极具潜力。越来越多证据表明IVM可用抗SARS-CoV-2病毒，但将IVM纳入COVID-19管理的最终呼吁仍然没有定论。因为FDA只评估了IVM在特定动物物种中的安全性和有效性，且IVM动物性药物会对人造成严重伤害。WHO认为IVM治疗COVID-19患者方面尚无定论，IVM在COVID-19中的有效性仍然存在不确定性，其中许多研究没有发现IVM对结局有效。展望未来，IVM或许有望和其他COVID-19治疗方法提供更明确的答案，但现阶段IVM治疗COVID-19不确定的风险仍在，建议不要使用IVM来预防或治疗COVID-19。
Abstract: Ivermectin (IVM) is a broad-spectrum antiparasitic drug approved by the Food and Drug Administration (FDA) that has shown antiviral activity against a variety of DNA and RNA viruses, including SARS-CoV-2; combined with low cost, strong availability, good tolerance and safety, it has great potential for clinical application of COVID-19. More and more evidence suggests that IVM may be used in COVID-19. But the final call to incorporate IVM into COVID-19 management remains inconclusive. Because the FDA has only evaluated the safety and efficacy of IVM in specific animal species, animal-based IVM drugs can cause serious harm to humans. In addition, WHO believes that IVM treatment of patients with COVID-19 is inconclusive, the effectiveness of IVM in COVID-19 is still uncertain, and many of these studies have not found IVM effective for many outcomes. Looking ahead, IVM may be expected to provide a more specific answer to the other COVID-19 treatment, but the risk of the IVM treatment of COVID-19 at this stage is still there, and it is recommended that IVM should not be used to prevent or treat COVID-19.
文章引用：车土玲, 蓝萍, 余春森, 苏裕盛. 伊维菌素在COVID-19的临床应用析论[J]. 自然科学, 2023, 11(2): 176-182. https://doi.org/10.12677/OJNS.2023.112020

参考文献

[1] Shirazi, F.M., Mirzaei, R., Nakhaee, S., Nejatian, A., Ghafari, S. and Mehrpour, O. (2022) Repurposing the Drug, Ivermectin, in COVID-19: Toxicological Points of View. European Journal of Medical Research, 27, Article No. 21. [Google Scholar] [CrossRef] [PubMed]
[2] González Canga, A., Sahagún Prieto, A.M., Diez Liébana, M.J., Martínez, N.F., Vega, M.S. and Garcia Vieitez, J.J. (2008) The Pharmacokinetics and Interactions of Ivermectin In Humans—A Mini-Review. The AAPS Journal, 10, 42-46. [Google Scholar] [CrossRef] [PubMed]
[3] Molento, M.B. (2020) COVID-19 and the Rush for Self-Medication and Self-Dosing with Ivermectin: A Word of Caution. One Health, 10, Article ID: 100148. [Google Scholar] [CrossRef] [PubMed]
[4] Formiga, F.R., Leblanc, R., de Souza Reboucas, J., Farias, L.P., de Oliveira, R.N. and Pena, L. (2021) Ivermectin: An Award-Winning Drug with Expected Antiviral Activity against COVID-19. Journal of Controlled Release, 329, 758-761. [Google Scholar] [CrossRef] [PubMed]
[5] Ahmed, S., Karim, M.M., Ross, A.G., Hossain, M.S., Clemens, J.D., Sumiya, M.K., Phru, C.S., Rahman, M., Zaman, K., Somani, J., et al. (2021) A Five-Day Course of Ivermectin for the Treatment of COVID-19 May Reduce the Duration of Illness. International Journal of Infectious Diseases, 103, 214-216. [Google Scholar] [CrossRef] [PubMed]
[6] Wolfrom, E., Chêne, G., Lejoly-Boisseau, H., Beylot, C., Geniaux, M. and Taïeb, A. (1996) [Chronic Urticaria and Toxocaracanis Infection. A Case-Control Study]. Annales de Dermatologie et de Vénéréologie, 123, 240-246. (In French)
[7] Jermain, B., Hanafin, P.O., Cao, Y., Lifschitz, A., Lanusse, C. and Rao, G.G. (2020) Development of a Minimal Physiologi-cally-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of Pharmaceutical Sciences, 109, 3574-3578. [Google Scholar] [CrossRef] [PubMed]
[8] Caly, L., Druce, J.D., Catton, M.G., Jans, D.A. and Wagstaff, K.M. (2020) The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro. Antiviral Re-search, 178, Article ID: 104787. [Google Scholar] [CrossRef] [PubMed]
[9] Wulan, W.N., Heydet, D., Walker, E.J., Gahan, M.E. and Ghildyal, R. (2015) Nucleocytoplasmic Transport of Nucleocapsid Proteins of Enveloped RNA Viruses. Frontiers in Microbiology, 6, Article 553. [Google Scholar] [CrossRef] [PubMed]
[10] Hiscox, J.A., Wurm, T., Wilson, L., Britton, P., Cavanagh, D. and Brooks, G. (2001) The Coronavirus Infectious Bronchitis Virus Nucleoprotein Localizes to the Nucleolus. Journal of Virology, 75, 506-512. [Google Scholar] [CrossRef] 
[11] Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S.A., Palese, P. and Baric, R.S. (2007) Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane. Journal of Virology, 81, 9812-9824. [Google Scholar] [CrossRef] 
[12] Mittal, N. and Mittal, R. (2021) Inhaled Route and An-ti-Inflammatory Action of Ivermectin: Do They Hold Promise in Fighting against COVID-19? Medical Hypotheses, 146, Article ID: 110364. [Google Scholar] [CrossRef] [PubMed]
[13] Sen Gupta, P.S., Biswal, S., Panda, S.K., Ray, A.K. and Rana, M.K. (2020) Binding Mechanism and Structural Insights into the Identified Protein Target of Covid-19 with in-Vitro Effective Drug Ivermectin. Journal of Biomolecular Structure and Dynamics, 1-10. [Google Scholar] [CrossRef] 
[14] Wagstaff, K.M., Rawlinson, S.M., Hearps, A.C. and Jans, D.A. (2011) An AlphaScreen®-Based Assay for High-Throughput Screening for Specific Inhibitors of Nuclear Import. Journal of Biomolecular Screening, 16, 192-200. [Google Scholar] [CrossRef] [PubMed]
[15] Heidary, F. and Gharebaghi, R. (2020) Ivermectin: A Sys-tematic Review from Antiviral Effects to COVID-19 Complementary Regimen. The Journal of Antibiotics, 73, 593-602. [Google Scholar] [CrossRef] [PubMed]
[16] Low, Z.Y., Yip, A.J.W. and Lal, S.K. (2022) Re-positioning Ivermectin for Covid-19 Treatment: Molecular Mechanisms of Action against SARS-CoV-2 Replication. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1868, Article ID: 166294. [Google Scholar] [CrossRef] [PubMed]
[17] Hellwig, M.D. and Maia, A. (2021) A COVID-19 Prophy-laxis? Lower Incidence Associated with Prophylactic Administration of Ivermectin. International Journal of Anti-microbial Agents, 57, Article ID: 106248. [Google Scholar] [CrossRef] [PubMed]
[18] Bernigaud, C., Guillemot, D., Ahmed-Belkacem, A., Grimaldi-Bensouda, L., Lespine, A., Berry, F., Softic, L., Chenost, C., Do-Pham, G., Giraudeau, B., et al. (2021) Oral Ivermectin for a Scabies Outbreak in a Long-Term Care Facility: Potential Value in Preventing COVID-19 and Associated Mortality. British Journal of Dermatology, 184, 1207-1209. [Google Scholar] [CrossRef] [PubMed]
[19] Vora, A., Arora, V.K., Behera, D. and Tripathy, S.K. (2020) White Paper on Ivermectin as a Potential Therapy for COVID-19. Indian Journal of Tuberculosis, 67, 448-451. [Google Scholar] [CrossRef] [PubMed]
[20] Bryant, A., Lawrie, T.A., Dowswell, T., Fordham, E.J., Mitch-ell, S., Hill, S.R. and Tham, T.C. (2021) Ivermectin for Prevention and Treatment of COVID-19 Infection: A Sys-tematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460. [Google Scholar] [CrossRef] 
[21] Hazan, S., Dave, S., Gunaratne, A.W., Dolai, S., Clancy, R.L., McCullough, P.A. and Borody, T.J. (2022) Effectiveness of Ivermectin-Based Multidrug Therapy in Severely Hypoxic, Ambulatory COVID-19 Patients. Future Microbiology, 17, 339-350. [Google Scholar] [CrossRef] [PubMed]
[22] DiNicolantonio, J.J., Barroso, J. and McCarty, M. (2020) Iver-mectin May Be a Clinically Useful Anti-Inflammatory Agent for Late-Stage COVID-19. Open Heart, 7, e001350. [Google Scholar] [CrossRef] [PubMed]
[23] Gupta, D., Sahoo, A.K. and Singh, A. (2020) Ivermectin: Potential Candidate for the Treatment of Covid 19. The Brazilian Journal of Infectious Diseases, 24, 369-371. [Google Scholar] [CrossRef] [PubMed]
[24] Kerr, L., Cadegiani, F.A., Baldi, F., Lobo, R.B., Assagra, W.L.O., Proenca, F.C., Kory, P., Hibberd, J.A. and Chamie-Quintero, J.J. (2022) Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching. Cureus, 14, e21272. [Google Scholar] [CrossRef] [PubMed]
[25] Reis, G., Silva, E., Silva, D.C.M., Thabane, L., Milagres, A.C., Ferreira, T.S., Dos Santos, C.V.Q., Campos, V.H.S., Nogueira, A.M.R., de Almeida, A., et al. (2022) Effect of Early Treatment with Ivermectin among Patients with Covid-19. New England Journal of Medicine, 386, 1721-1731. [Google Scholar] [CrossRef] 
[26] Lim, S.C.L., Hor, C.P., Tay, K.H., Mat Jelani, A., Tan, W.H., Ker, H.B., Chow, T.S., Zaid, M., Cheah, W.K., Lim, H.H., et al. (2022) Efficacy of Ivermectin Treatment on Disease Progression among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Ran-domized Clinical Trial. JAMA Internal Medicine, 182, 426-435. [Google Scholar] [CrossRef] [PubMed]
[27] Buonfrate, D., Chesini, F., Martini, D., Roncaglioni, M.C., Ojeda Fernandez, M.L., Alvisi, M.F., De Simone, I., Rulli, E., Nobili, A., Casalini, G., et al. (2022) High-Dose Ivermectin for Early Treatment of COVID-19 (COVER Study): A Randomised, Double-Blind, Multicentre, Phase II, Dose-Finding, Proof-of-Concept Clinical Trial. International Journal of Antimicrobial Agents, 59, Article ID: 106516. [Google Scholar] [CrossRef] [PubMed]
[28] Ozer, M., Goksu, S.Y., Conception, R., Ulker, E., Balderas, R.M., Mahdi, M., Manning, Z., To, K., Effendi, M., Anandakrishnan, R., et al. (2022) Effectiveness and Safety of Ivermectin in COVID-19 Patients: A Prospective Study at A Safety-Net Hospital. Journal of Medical Vi-rology, 94, 1473-1480. [Google Scholar] [CrossRef] [PubMed]
[29] Roman, Y.M., Burela, P.A., Pasupuleti, V., Piscoya, A., Vidal, J.E. and Hernandez, A.V. (2022) Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Infectious Diseases, 74, 1022-1029. [Google Scholar] [CrossRef] [PubMed]
[30] Popp, M., Stegemann, M., Metzendorf, M.I., Gould, S., Kranke, P., Meybohm, P., Skoetz, N. and Weibel, S. (2021) Ivermectin for Preventing and Treating COVID-19. Cochrane Database of Systematic Reviews, 7, Article ID: CD015017. [Google Scholar] [CrossRef] 
[31] Johnson-Arbor, K. (2022) Ivermectin: A Mini-Review. Clinical Toxicology, 60, 571-575. [Google Scholar] [CrossRef] [PubMed]
[32] Camprubi, D., Almuedo-Riera, A., Marti-Soler, H., So-riano, A., Hurtado, J.C., Subira, C., Grau-Pujol, B., Krolewiecki, A. and Munoz, J. (2020) Lack of Efficacy of Standard Doses of Ivermectin in Severe COVID-19 Patients. PLOS ONE, 15, e0242184. [Google Scholar] [CrossRef] [PubMed]
[33] Sen Gupta, P.S. and Rana, M.K. (2020) Ivermectin, Fa-motidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19. ACS Phar-macology & Translational Science, 3, 1037-1038. [Google Scholar] [CrossRef] [PubMed]
[34] Schmith, V.D., Zhou, J.J. and Lohmer, L.R.L. (2020) The Ap-proved Dose of Ivermectin Alone Is Not the Ideal Dose for the Treatment of COVID-19. Clinical Pharmacology & Therapeutics, 108, 762-765. [Google Scholar] [CrossRef] [PubMed]
[35] Solomon, S. (2020) FDA Letter to Stakeholders: Do Not Use Ivermectin Intended for Animals as Treatment for COVID-19 in Humans. https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans
[36] World Health Organization (2021) WHO Advises That Iver-mectin Only Be Used to Treat COVID-19 within Clinical Trials. World Health Organization, Geneva.
[37] Merck Statement on Ivermectin Use during the COVID-19 Pandemic. Merck. https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic